Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

GoodRx vs TeleDocs360

GoodRx
Graded #116

Higher grade

vs+14.399999999999991
TeleDocs360
Graded #444

Lower grade

The verdict

GoodRx takes it — 69.6/100 to 55.2/100.

GoodRx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. GoodRx (NASDAQ: GDRX) is the largest US prescription savings platform.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueGoodRx +53
80
27
Dose & formulationTeleDocs360 +5
70
75
Clinical oversightTeleDocs360 +15
69
84
Labs & monitoringTeleDocs360 +1
51
52
FulfillmentGoodRx +21
81
60
Contract termsGoodRx +35
55
20
GoodRx · left barTeleDocs360 · right bar

The numbers

MetricGoodRxTeleDocs360
WeighScore69.6/10055.2/100
GradeCC
Scorecard rank#116#444
SemaglutideNot disclosed$399/mo (compounded)
Tirzepatide$299/mo (brand Zepbound)$399/mo (compounded)
CoverageAll 50 statesCoverage not published
Brand-name accessYesCompounded only
Oral / sublingualInjection onlyYes
GoodRx

Graded #116 · C

Strengths

  • $149/month self-pay for brand-name Foundayo (orforglipron) — matches the lowest cash price at launch, far below typical retail
  • $299/month self-pay for Zepbound KwikPen — well under Lilly's typical cash list price
  • Honored at 70,000+ US pharmacies — the largest retail redemption network of any GLP-1 channel we cover
  • No membership fee — bring your own prescription and present the discount card at the pharmacy counter
  • Brand-name FDA-approved medication, not compounded

Where it loses points

  • Requires a valid prescription — GoodRx is a discount card, not a prescriber; you still need a clinician to write the script
  • Self-pay only — does not apply toward insurance benefits or deductibles
  • Headline price applies to the lowest Foundayo dose; higher doses may cost more
  • No compounded GLP-1 options — not the channel for compounded semaglutide or tirzepatide
  • Pricing can change as Lilly's manufacturer coupon program evolves
TeleDocs360

Graded #444 · C

Strengths

  • Transparent $399/month base pricing for standard dosing
  • Multiple GLP-1 options including injectable and oral semaglutide
  • Cash-pay model with HSA/FSA card acceptance
  • Fast online intake and 24-hour prescription approval
  • Cancel anytime between shipments

Where it loses points

  • Compounded-only; no FDA-approved branded options
  • No published state availability list
  • No individual provider credentials or board certifications shown
  • Higher doses increase cost

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard